Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology

Kathy Sengmany, Shane D. Hellyer, Sabine Albold, Taide Wang, P. Jeffrey Conn, Lauren T. May, Arthur Christopoulos, Katie Leach, Karen J. Gregory

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu 5 ) have been proposed as potential therapies for various CNS disorders. These ligands bind to sites distinct from the orthosteric (or endogenous) ligand, often with improved subtype selectivity and spatio-temporal control over receptor responses. We recently revealed that mGlu 5 allosteric agonists and positive allosteric modulators exhibit biased agonism and/or modulation. To establish whether negative allosteric modulators (NAMs) engender similar bias, we rigorously characterized the pharmacology of eight diverse mGlu 5 NAMs. Radioligand inhibition binding studies revealed novel modes of interaction with mGlu 5 for select NAMs, with biphasic or incomplete inhibition of the radiolabeled NAM, [ 3 H]methoxy-PEPy. We assessed mGlu 5 -mediated intracellular Ca 2+ (iCa 2+ ) mobilization and inositol phosphate (IP 1 ) accumulation in HEK293A cells stably expressing low levels of mGlu 5 (HEK293A-rat mGlu 5 -low) and mouse embryonic cortical neurons. The apparent affinity of acetylenic NAMs, MPEP, MTEP and dipraglurant, was dependent on the signaling pathway measured, agonist used, and cell type (HEK293A-rat mGlu 5 -low versus mouse cortical neurons). In contrast, the acetylenic partial NAM, M-5MPEP, and structurally distinct NAMs (VU0366248, VU0366058, fenobam), had similar affinity estimates irrespective of the assay or cellular background. Biased modulation was evident for VU0366248 in mouse cortical neurons where it was a NAM for DHPG-mediated iCa 2+ mobilization, but neutral with DHPG in IP 1 accumulation assays. Overall, this study highlights the inherent complexity in mGlu 5 NAM pharmacology that we hypothesize may influence interpretation when translating into preclinical models and beyond in the design and development of novel therapeutics for neuropsychiatric and neurological disorders.

Original languageEnglish
Pages (from-to)83-96
Number of pages14
JournalNeuropharmacology
Volume149
DOIs
Publication statusPublished - 1 May 2019

Keywords

  • (L-glutamic acid PubChem CID: 33032)
  • (PubChem CID: 108001)
  • (PubChem CID: 16036762)
  • (PubChem CID: 162834)
  • (PubChem CID: 3025961)
  • (PubChem CID: 44557636)
  • (PubChem CID: 57328392)
  • (PubChem CID: 9794218)
  • Biased modulation
  • DHPG
  • dipraglurant
  • fenobam
  • Glutamate
  • Kinetics
  • M-5MPEP
  • Metabotropic glutamate receptor 5
  • MPEP
  • MTEP
  • Negative allosteric modulator
  • VU0366058

Cite this

@article{711c384654d7406a8f86db762e24209b,
title = "Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology",
abstract = "Allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu 5 ) have been proposed as potential therapies for various CNS disorders. These ligands bind to sites distinct from the orthosteric (or endogenous) ligand, often with improved subtype selectivity and spatio-temporal control over receptor responses. We recently revealed that mGlu 5 allosteric agonists and positive allosteric modulators exhibit biased agonism and/or modulation. To establish whether negative allosteric modulators (NAMs) engender similar bias, we rigorously characterized the pharmacology of eight diverse mGlu 5 NAMs. Radioligand inhibition binding studies revealed novel modes of interaction with mGlu 5 for select NAMs, with biphasic or incomplete inhibition of the radiolabeled NAM, [ 3 H]methoxy-PEPy. We assessed mGlu 5 -mediated intracellular Ca 2+ (iCa 2+ ) mobilization and inositol phosphate (IP 1 ) accumulation in HEK293A cells stably expressing low levels of mGlu 5 (HEK293A-rat mGlu 5 -low) and mouse embryonic cortical neurons. The apparent affinity of acetylenic NAMs, MPEP, MTEP and dipraglurant, was dependent on the signaling pathway measured, agonist used, and cell type (HEK293A-rat mGlu 5 -low versus mouse cortical neurons). In contrast, the acetylenic partial NAM, M-5MPEP, and structurally distinct NAMs (VU0366248, VU0366058, fenobam), had similar affinity estimates irrespective of the assay or cellular background. Biased modulation was evident for VU0366248 in mouse cortical neurons where it was a NAM for DHPG-mediated iCa 2+ mobilization, but neutral with DHPG in IP 1 accumulation assays. Overall, this study highlights the inherent complexity in mGlu 5 NAM pharmacology that we hypothesize may influence interpretation when translating into preclinical models and beyond in the design and development of novel therapeutics for neuropsychiatric and neurological disorders.",
keywords = "(L-glutamic acid PubChem CID: 33032), (PubChem CID: 108001), (PubChem CID: 16036762), (PubChem CID: 162834), (PubChem CID: 3025961), (PubChem CID: 44557636), (PubChem CID: 57328392), (PubChem CID: 9794218), Biased modulation, DHPG, dipraglurant, fenobam, Glutamate, Kinetics, M-5MPEP, Metabotropic glutamate receptor 5, MPEP, MTEP, Negative allosteric modulator, VU0366058",
author = "Kathy Sengmany and Hellyer, {Shane D.} and Sabine Albold and Taide Wang and Conn, {P. Jeffrey} and May, {Lauren T.} and Arthur Christopoulos and Katie Leach and Gregory, {Karen J.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.neuropharm.2019.02.005",
language = "English",
volume = "149",
pages = "83--96",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier",

}

Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology. / Sengmany, Kathy; Hellyer, Shane D.; Albold, Sabine; Wang, Taide; Conn, P. Jeffrey; May, Lauren T.; Christopoulos, Arthur; Leach, Katie; Gregory, Karen J.

In: Neuropharmacology, Vol. 149, 01.05.2019, p. 83-96.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology

AU - Sengmany, Kathy

AU - Hellyer, Shane D.

AU - Albold, Sabine

AU - Wang, Taide

AU - Conn, P. Jeffrey

AU - May, Lauren T.

AU - Christopoulos, Arthur

AU - Leach, Katie

AU - Gregory, Karen J.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu 5 ) have been proposed as potential therapies for various CNS disorders. These ligands bind to sites distinct from the orthosteric (or endogenous) ligand, often with improved subtype selectivity and spatio-temporal control over receptor responses. We recently revealed that mGlu 5 allosteric agonists and positive allosteric modulators exhibit biased agonism and/or modulation. To establish whether negative allosteric modulators (NAMs) engender similar bias, we rigorously characterized the pharmacology of eight diverse mGlu 5 NAMs. Radioligand inhibition binding studies revealed novel modes of interaction with mGlu 5 for select NAMs, with biphasic or incomplete inhibition of the radiolabeled NAM, [ 3 H]methoxy-PEPy. We assessed mGlu 5 -mediated intracellular Ca 2+ (iCa 2+ ) mobilization and inositol phosphate (IP 1 ) accumulation in HEK293A cells stably expressing low levels of mGlu 5 (HEK293A-rat mGlu 5 -low) and mouse embryonic cortical neurons. The apparent affinity of acetylenic NAMs, MPEP, MTEP and dipraglurant, was dependent on the signaling pathway measured, agonist used, and cell type (HEK293A-rat mGlu 5 -low versus mouse cortical neurons). In contrast, the acetylenic partial NAM, M-5MPEP, and structurally distinct NAMs (VU0366248, VU0366058, fenobam), had similar affinity estimates irrespective of the assay or cellular background. Biased modulation was evident for VU0366248 in mouse cortical neurons where it was a NAM for DHPG-mediated iCa 2+ mobilization, but neutral with DHPG in IP 1 accumulation assays. Overall, this study highlights the inherent complexity in mGlu 5 NAM pharmacology that we hypothesize may influence interpretation when translating into preclinical models and beyond in the design and development of novel therapeutics for neuropsychiatric and neurological disorders.

AB - Allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu 5 ) have been proposed as potential therapies for various CNS disorders. These ligands bind to sites distinct from the orthosteric (or endogenous) ligand, often with improved subtype selectivity and spatio-temporal control over receptor responses. We recently revealed that mGlu 5 allosteric agonists and positive allosteric modulators exhibit biased agonism and/or modulation. To establish whether negative allosteric modulators (NAMs) engender similar bias, we rigorously characterized the pharmacology of eight diverse mGlu 5 NAMs. Radioligand inhibition binding studies revealed novel modes of interaction with mGlu 5 for select NAMs, with biphasic or incomplete inhibition of the radiolabeled NAM, [ 3 H]methoxy-PEPy. We assessed mGlu 5 -mediated intracellular Ca 2+ (iCa 2+ ) mobilization and inositol phosphate (IP 1 ) accumulation in HEK293A cells stably expressing low levels of mGlu 5 (HEK293A-rat mGlu 5 -low) and mouse embryonic cortical neurons. The apparent affinity of acetylenic NAMs, MPEP, MTEP and dipraglurant, was dependent on the signaling pathway measured, agonist used, and cell type (HEK293A-rat mGlu 5 -low versus mouse cortical neurons). In contrast, the acetylenic partial NAM, M-5MPEP, and structurally distinct NAMs (VU0366248, VU0366058, fenobam), had similar affinity estimates irrespective of the assay or cellular background. Biased modulation was evident for VU0366248 in mouse cortical neurons where it was a NAM for DHPG-mediated iCa 2+ mobilization, but neutral with DHPG in IP 1 accumulation assays. Overall, this study highlights the inherent complexity in mGlu 5 NAM pharmacology that we hypothesize may influence interpretation when translating into preclinical models and beyond in the design and development of novel therapeutics for neuropsychiatric and neurological disorders.

KW - (L-glutamic acid PubChem CID: 33032)

KW - (PubChem CID: 108001)

KW - (PubChem CID: 16036762)

KW - (PubChem CID: 162834)

KW - (PubChem CID: 3025961)

KW - (PubChem CID: 44557636)

KW - (PubChem CID: 57328392)

KW - (PubChem CID: 9794218)

KW - Biased modulation

KW - DHPG

KW - dipraglurant

KW - fenobam

KW - Glutamate

KW - Kinetics

KW - M-5MPEP

KW - Metabotropic glutamate receptor 5

KW - MPEP

KW - MTEP

KW - Negative allosteric modulator

KW - VU0366058

UR - http://www.scopus.com/inward/record.url?scp=85062156730&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2019.02.005

DO - 10.1016/j.neuropharm.2019.02.005

M3 - Article

VL - 149

SP - 83

EP - 96

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -